Abstract | BACKGROUND: METHODS: We performed a retrospective chart review of patients treated with IV or IM PEG-ASP at The Hospital for Sick Children, Toronto, Canada, from March 1, 2010 to January 1, 2012. The incidence and severity of allergic reactions attributed to PEG-ASP were documented. Patient age, sex, route of PEG-ASP administration, disease (risk group and lineage) and mean time interval between PEG-ASP doses were evaluated as possible risk factors for allergic reaction. RESULTS: A total of 109 patients were included. There were 14 (35 %) allergic reactions among 40 patients who received IV, compared with eight (12 %) of the 69 who received IM [odds ratio (OR) 4.11, 95 % confidence interval (CI) 1.54-10.97, p = 0.005]. In multivariable logistic regression adjusting for disease risk group, route (IV vs. IM) remained independently significant (p = 0.011). Patients with standard-risk ALL had a lower risk of experiencing an allergic reaction associated with PEG-ASP compared with patients in high-risk disease risk groups (collectively referred to as "other"; 11 vs. 31 %, OR 3.36, 95 % CI 1.16-9.72, p = 0.025). CONCLUSIONS: IV PEG-ASP is associated with a significantly higher rate of allergic reactions than IM. The clinical preference for IV PEG-ASP may warrant re-evaluation.
|
Authors | Lesleigh S Abbott, Maria Zakova, Furqan Shaikh, Nisha Shewaramani, Angela Punnett, L Lee Dupuis |
Journal | Paediatric drugs
(Paediatr Drugs)
Vol. 17
Issue 4
Pg. 315-21
(Aug 2015)
ISSN: 1179-2019 [Electronic] Switzerland |
PMID | 25862348
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Polyethylene Glycols
- pegaspargase
- Asparaginase
|
Topics |
- Administration, Intravenous
- Adolescent
- Asparaginase
(administration & dosage, adverse effects)
- Canada
- Child
- Child, Preschool
- Drug Hypersensitivity
(etiology)
- Female
- Humans
- Infant
- Infant, Newborn
- Injections, Intramuscular
- Male
- Polyethylene Glycols
(administration & dosage, adverse effects)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy)
- Retrospective Studies
- Risk Factors
|